As mentioned previously, CCK-8 assays showed that HOXA-AS3 knockdown in NSCLC cells resulted in a significant reduction in viability in response to cisplatin compared with that in the controls. This evidence concerns the gene HOXA-AS3 and non-small cell lung carcinoma.